ETF Holdings Breakdown of COGT

COGT institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-29	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	58,914	USD 832,455
2025-09-29	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	30,449	USD 430,244
2025-09-29	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	79,180	USD 1,118,813
2025-09-29	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	79,180	USD 1,118,813
2025-09-29	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	866	USD 12,237
Total =		248,589	USD 3,512,562

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with COGT

Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $20.00

Cogent Biosciences (NASDAQ:COGT – Get Free Report) had its price target lifted by equities researchers at Guggenheim from $17.00 to $20.00 in a research note issued on Monday, MarketBeat.com reports. The firm currently has a “buy” rating on the technology company’s stock. Guggenheim’s price objective indicates a potential upside of 63.53% from the stock’s previous […] - 2025-08-27 02:08:48

Arizona State Retirement System Has $123,000 Position in Cogent Biosciences, Inc. (NASDAQ:COGT)

Arizona State Retirement System grew its stake in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 18.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,567 shares of the technology company’s stock after purchasing an additional 3,142 shares during the […] - 2025-07-24 04:38:50

Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $22.00 at Citigroup

Cogent Biosciences (NASDAQ:COGT – Free Report) had its price objective boosted by Citigroup from $15.00 to $22.00 in a research note issued to investors on Friday morning,Benzinga reports. Citigroup currently has a buy rating on the technology company’s stock. Several other equities analysts have also recently commented on COGT. HC Wainwright boosted their target price […] - 2025-07-21 04:55:01

Cogent Biosciences (NASDAQ:COGT) Trading 9% Higher Following Analyst Upgrade

Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report)’s share price traded up 9% during trading on Wednesday after JPMorgan Chase & Co. raised their price target on the stock from $25.00 to $29.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Cogent Biosciences traded as high as $10.12 and last traded […] - 2025-07-11 02:22:49

Cogent Biosciences (NASDAQ:COGT) Sees Large Volume Increase on Analyst Upgrade

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) saw strong trading volume on Tuesday after HC Wainwright raised their price target on the stock from $12.00 to $22.00. HC Wainwright currently has a buy rating on the stock. 4,989,146 shares changed hands during mid-day trading, an increase of 236% from the previous session’s […] - 2025-07-10 02:52:43

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of “Moderate Buy” by Brokerages

Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) has received a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-07-08 05:26:50

Pre-Market Most Active for Jul 7, 2025 : TSLL, TSLA, TSLQ, COGT, BBAI, SQQQ, NVDA, HLN, CRCL, NIO, OSCR, QBTS

The NASDAQ 100 Pre-Market Indicator is down -99.52 to 22,767.45. The total Pre-Market volume is currently 171,325,842 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is -1.4 at $10.13, with 43,244,717 s - 2025-07-07 09:29:58

Wedbush Reiterates “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT)

Cogent Biosciences (NASDAQ:COGT – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at Wedbush in a report issued on Monday,RTT News reports. They presently have a $10.00 target price on the technology company’s stock. Wedbush’s price objective would suggest a potential upside of 38.50% from the stock’s previous close. A number […] - 2025-07-02 02:56:48

Needham & Company LLC Reiterates Hold Rating for Cogent Biosciences (NASDAQ:COGT)

Cogent Biosciences (NASDAQ:COGT – Get Free Report)‘s stock had its “hold” rating restated by equities research analysts at Needham & Company LLC in a note issued to investors on Tuesday,Benzinga reports. Several other research firms also recently commented on COGT. Scotiabank started coverage on Cogent Biosciences in a research note on Friday, March 7th. They […] - 2025-06-19 02:26:49

Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Position Lessened by Wellington Management Group LLP

Wellington Management Group LLP decreased its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 16.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 284,850 shares of the technology company’s stock after selling 57,473 shares during the quarter. Wellington Management Group LLP’s holdings in Cogent Biosciences were worth $2,222,000 at […] - 2025-06-06 05:34:49

Nuveen Asset Management LLC Has $2.44 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)

Nuveen Asset Management LLC lessened its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 0.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 313,099 shares of the technology company’s stock after selling 1,896 shares during the quarter. Nuveen Asset Management LLC’s holdings in Cogent Biosciences were worth $2,442,000 at […] - 2025-06-03 04:58:48

Cogent Biosciences, Inc. (NASDAQ:COGT) Position Increased by ProShare Advisors LLC

ProShare Advisors LLC increased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 30.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,074 shares of the technology company’s stock after purchasing an additional 7,267 shares during the period. […] - 2025-06-01 05:44:58

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation […] - 2025-05-26 05:29:06

HC Wainwright Has Lowered Expectations for Cogent Biosciences (NASDAQ:COGT) Stock Price

Cogent Biosciences (NASDAQ:COGT – Get Free Report) had its price target lowered by analysts at HC Wainwright from $14.00 to $12.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the technology company’s stock. HC Wainwright’s price target would indicate a potential upside of […] - 2025-05-22 03:12:43

30,300 Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) Purchased by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp purchased a new position in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 30,300 shares of the technology company’s stock, valued at approximately $236,000. Several other hedge funds […] - 2025-05-21 05:26:52

D. E. Shaw & Co. Inc. Decreases Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)

D. E. Shaw & Co. Inc. lowered its position in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 25.6% during the 4th quarter, HoldingsChannel reports. The fund owned 339,988 shares of the technology company’s stock after selling 117,240 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Cogent Biosciences were worth $2,652,000 […] - 2025-05-20 04:57:06

Schonfeld Strategic Advisors LLC Takes $78,000 Position in Cogent Biosciences, Inc. (NASDAQ:COGT)

Schonfeld Strategic Advisors LLC purchased a new stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,000 shares of the technology company’s stock, valued at approximately $78,000. A number of […] - 2025-05-15 05:40:52

Dimensional Fund Advisors LP Sells 48,771 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)

Dimensional Fund Advisors LP lessened its position in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 6.2% in the fourth quarter, HoldingsChannel reports. The firm owned 743,652 shares of the technology company’s stock after selling 48,771 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Cogent Biosciences were worth $5,800,000 as of its most […] - 2025-05-12 04:50:50

Cogent Biosciences Sees Unusually High Options Volume (NASDAQ:COGT)

Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) was the recipient of unusually large options trading activity on Thursday. Investors purchased 20,016 call options on the company. This is an increase of 5,019% compared to the typical volume of 391 call options. Cogent Biosciences Stock Up 8.1 % Shares of NASDAQ:COGT opened at $5.63 on […] - 2025-05-02 02:09:01

Legal & General Group Plc Sells 2,304 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)

Legal & General Group Plc cut its position in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 3.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,541 shares of the technology company’s stock after selling 2,304 shares during […] - 2025-04-30 04:46:50

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.43 Consensus Target Price from Analysts

Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight ratings firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation […] - 2025-04-29 04:41:03

Alliancebernstein L.P. Buys 382,882 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)

Alliancebernstein L.P. lifted its position in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 466.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 464,942 shares of the technology company’s stock after acquiring an additional 382,882 shares during the quarter. Alliancebernstein […] - 2025-04-15 04:52:58

KLP Kapitalforvaltning AS Acquires Shares of 11,300 Cogent Biosciences, Inc. (NASDAQ:COGT)

KLP Kapitalforvaltning AS bought a new stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 11,300 shares of the technology company’s stock, valued at approximately $88,000. Other hedge funds and other institutional investors […] - 2025-04-11 04:44:59

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) have received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy […] - 2025-04-04 04:57:00

Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Holdings Boosted by Intech Investment Management LLC

Intech Investment Management LLC boosted its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 99.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,657 shares of the technology company’s stock after buying an additional 28,233 shares during the quarter. […] - 2025-03-25 06:31:05

Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Sold by AlphaQuest LLC

AlphaQuest LLC reduced its stake in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 67.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,012 shares of the technology company’s stock after selling 16,970 shares during the quarter. AlphaQuest LLC’s holdings in Cogent Biosciences were […] - 2025-03-20 06:13:09

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target […] - 2025-03-10 05:10:47

Cogent Biosciences (NASDAQ:COGT) Now Covered by Scotiabank

Scotiabank assumed coverage on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a report issued on Friday morning, Marketbeat Ratings reports. The brokerage issued a sector outperform rating and a $17.00 price objective on the technology company’s stock. COGT has been the subject of several other research reports. Wedbush reaffirmed a “neutral” rating and […] - 2025-03-10 03:50:48

New York State Common Retirement Fund Acquires 2,200 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)

New York State Common Retirement Fund boosted its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 10.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,102 shares of the technology company’s stock after purchasing an additional 2,200 shares […] - 2025-03-06 08:19:23

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Rating of “Moderate Buy” by Brokerages

Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective […] - 2025-02-13 06:44:53

Back to Listing

Disclaimer